Clinical trials: Neoadjuvant Chemoradiotherapy
Rectal Cancer
Genotype-driven Weekly Irinotecan Liposomes in Combination With Capecitabine-based Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer
This study is a multicenter, open, and phase I dose increasing clinical study. Based on the UGT1A1 * 28 and * 6 genotypes of patients with locally advanced rectal cancer, determine the dose limiting toxicity (DLT) and maximum…
- Trial name
- NCT06300489
- Testing
- irinotecan liposomes+capecitabine
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Colorectal Cancer
Capecitabine and Oxaliplatin or Standard Follow-Up Care in Treating Patients Who Have Undergone Surgery for Locally Advanced Rectal Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00427713
- Testing
- capecitabine, oxaliplatin, adjuvant therapy
- Where
- 72 sites in United Kingdom
- Volunteers
- 800 people
- Sponsor
- Cancer Research UK
Resectable Esophageal Squamous Cell Carcinoma
Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.
The purpose of this study is to explore the effectiveness and safety of neoadjuvant immune combined chemotherapy or radiochemotherapy compared with traditional neoadjuvant radiochemotherapy in patients with locally advanced…
- Trial name
- NCT05043688
- Testing
- Camrelizumab, radiotherapy
- Where
- 5 sites in China
- Volunteers
- 426 people
- Sponsor
- Zhigang Li
Rectal Cancers, Pathological Complete Response
Predicting Pathological Complete Response in Rectal Cancer Using Machine Learning
This study aims to develop and validate a robust machine learning-based prediction model utilizing baseline clinical data and magnetic resonance imaging (MRI) features.
- Conditions
- Rectal Cancers, Pathological Complete Response, Neoadjuvant Chemoradiotherapy, Machine Learning
- Trial name
- NCT07509632
- Testing
- No interventions
- Where
- China
- Volunteers
- 320 people
- Sponsor
- Peking University People's Hospital
Esophageal Cancer, Esophageal Adenocarcinoma
Preoperative Image-guided Identification of Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer
Rationale: For locally advanced esophageal cancer the standard treatment consists of 5 weeks of neoadjuvant chemoradiotherapy (nCRT) followed by surgery.
- Conditions
- Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms
- Trial name
- PRIDE (NCT03474341)
- Testing
- MRI, PET-CT, Endoscopy
- Where
- 4 sites in Netherlands
- Volunteers
- 200 people
- Sponsor
- UMC Utrecht
Locally Advanced Rectal Cancer
Evaluating Trifluridine/Tipiracil Based Chemoradiation in Locally Advanced Rectal Cancer - The Phase I/II TARC Trial
Seamless phase I/II trial with phase I part for determination of maximum tolerated dose (MTD) of Trifluridine/tipiracil, followed by a randomized phase II trial (randomization ratio 2:1) with an experimental arm with…
- Trial name
- NCT04177602
- Testing
- Trifluridine/tipiracil chemoradiation, Capecitabine based chemoradiation
- Where
- 8 sites in Germany
- Volunteers
- 10 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Pancreatic Cancer
Neoadjuvant Treatment in Resectable Pancreatic Cancer
Sequential Neoadjuvant Chemoradiotherapy (CRT) Followed by Curative Surgery vs. Primary Surgery Alone for Resectable, Non-metastasized Pancreatic Adenocarcinoma
- Trial name
- NEOPA (NCT01900327)
- Testing
- External Beam Radiation, Gemcitabine neoadjuvant, Surgery
- Where
- 16 sites in Germany
- Volunteers
- 32 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Time
Exploring the Optimal Timing of Minimally Invasive Surgery for Esophageal Squamous Cell Carcinoma
The optimal interval between neoadjuvant chemradiotherapy and esophagectomy is still a question that needs to be explored for patients with esophageal squamous cell carcinoma.
- Trial name
- NCT06364566
- Testing
- Neoadjuvant chemradiotherapy, Minimally invasive esophagectomy
- Where
- China
- Volunteers
- 303 people
- Sponsor
- Shanghai Zhongshan Hospital
Neoplasm, Esophagus, Neoplasm, Squamous Cell
Primary Tumor Burden Score:A Novel Staging Parameter for ESCC After nCRT
In this case-only study, the investigators try to define a novel staging parameter, the Primary Tumor Burden Score (PTBS).
- Trial name
- NCT05839002
- Testing
- nCRT
- Volunteers
- 187 people
- Sponsor
- Fudan University
Stomach Neoplasms, Esophagogastric Junction Disorder
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
NeoRacing is a randomized phase II trial carried out at Fudan University Shanghai Cancer Center (FUSCC) in China. The study can be divided into the screening stage, treatment stage and follow-up stage.
- Conditions
- Stomach Neoplasms, Esophagogastric Junction Disorder, Neoadjuvant Therapy, Chemoradiotherapy
- Trial name
- NeoRacing (NCT05161572)
- Testing
- Oxaliplatin, Tegafur-Gimeracil-Oteracil, Sintilimab
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Fudan University
Locally Advanced Rectal Cancer (LARC)
Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for High-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled Trial
The goal of this clinical trial is to learn whether adding ipilimumab N01 to standard pre-surgery treatment with radiation, chemotherapy, and sintilimab can improve outcomes for people with high-risk, locally advanced rectal…
- Trial name
- NCT07879586
- Testing
- Ipilimumab & Sintilimab, Sintilimab
- Volunteers
- 120 people
- Sponsor
- Yao Hongwei
Neoadjuvant Therapy, Esophageal Squamous Cell Carcinoma
A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
The goal of this interventional study is to compare the safety and efficacy of neoadjuvant immunotherapy plus chemotherapy and anlotinib versus immunotherapy combined with concurrent chemoradiotherapy in the treatment of locally…
- Trial name
- NCT06354530
- Testing
- anlotinib, Thoracic radiotherapy
- Where
- China
- Volunteers
- 266 people
- Sponsor
- Army Medical Center of PLA
Human Papilloma Virus, HPV
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers
Doctors leading this study hope to learn about the safety and effectiveness of combining medications HB-201 and HB-202 (also known as TheraT® vectors) with chemotherapy using carboplatin and paclitaxel in the beginning of the…
- Conditions
- Human Papilloma Virus, HPV, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer
- Trial name
- NCT05108870
- Testing
- HB-201, HB-202, Carboplatin
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Chicago
Rectal Cancer
Neoadjuvant Radiochemotherapy Combined With QL1706 for Low Rectal Cancer
This study investigates the efficacy of neoadjuvant radiotherapy combined with QL1706 in MSS-type low-grade rectal cancer. This study is a prospective multicohort study, with cohort 1 intended to include patients with low grade…
- Trial name
- NCT06931873
- Testing
- SCRT+Capoex+QL706, LCRT+Capoex+QL706
- Volunteers
- 60 people
- Sponsor
- Changhai Hospital
Ewing Sarcoma, Bone Neoplasms
Neoadjuvant Radiotherapy and Surgery for High-Risk Localized Ewing Sarcoma
This is a single-center, single-arm, prospective observational study to evaluate the long-term local control rate, safety, and efficacy of preoperative neoadjuvant radiotherapy (36-45 Gy) followed by sequential radical surgery…
- Trial name
- NCT07620431
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Peking University People's Hospital
Oncology
ExeNTrO: Exercise During Neoadjuvant Chemoradiation Treatment to Improve Rectal and Esophageal Cancer Outcome - Pilot Trial
The goals of this study is to 1) evaluate feasibility and fidelity of a three-arm RCT containing a twice-weekly exercise intervention supervised by a first-line (oncology) physiotherapist and a 5-day weekly in-hospital exercise…
- Trial name
- ExeNTrO (NCT05686213)
- Testing
- combined aerobic exercise + resistance exercise intervention (AE + RE), Aerobic exercise prior to daily radiotherapy sessions (ExPR)
- Where
- Netherlands
- Volunteers
- 39 people
- Sponsor
- Radboud University Medical Center